The average of price targets set by Wall Street analysts indicates a potential upside of 84.5% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...

Beam Therapeutics (BEAM – Research Report) received a Buy rating and a $37.00 price target from Bernstein analyst William Pickering today. The ...

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company at the forefront of precision genetic medicines with a market capitalization of $1.87 billion, is navigating a critical juncture in its ...

Beam Therapeutics (BEAM) announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the ...